Abstract:
Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
Abstract:
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract:
The present invention relates to a method of generating hypoallergenic glycoproteins in mutated or transgenic plants, parts of these plants, or plant cells produced therefrom, and also to the corresponding mutated or transgenic plants, plant parts and plant cells, in which the activity of the enzyme Golgi a-mannosidase II is eliminated or reduced, and which produce hypoallergenic heterologous glycoproteins.
Abstract:
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract:
Die vorliegende Erfindung betrifft ein Verfahren zur Erzeugung von hypoallergenen Glykoproteinen in mutierten oder transgenen Pflanzen, Teilen dieser Pflanzen oder daraus hergestellten Pflanzenzellen sowie die entsprechenden mutierten oder transgenen Pflanzen, Pflanzenteile und Pflanzenzellen, bei welchen die Aktivität des Enzyms Golgi α-Mannosidase II beseitigt oder verringert ist und welche hypoallergene heterologe Glykoproteine produzieren.
Abstract:
A method for producing human-like glycoproteins by expressing a Class 2 α-mannosidase having a substrate specificity for Manαl,3 and Manαl,6 glycosidic linkages in a lower eukaryote is disclosed. Hydrolysis of these linkages on oligosaccharides produces substrates for further N-glycan processing in the secretory pathway.
Abstract:
The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for alpha-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the contemplated vectors are also included in this invention.
Abstract:
Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
Abstract:
The present invention relates to methods for altering the structure of N-glycans in fun-gal cells and to fungal cells having an altered N-glycan structure.
Abstract:
A method for producing human-like glycoproteins by expressing a Class 2 alpha-mannosidase having a substrate specificity for Manalphal,3 and Manalphal,6 glycosidic linkages in a lower eukaryote is disclosed. Hydrolysis of these linkages on oligosaccharides produces substrates for further N-glycan processing in the secretory pathway.